The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Tau-positron emission tomography correlates with neuropathology findings.
Open accessAbstract
INTRODUCTION: Comparison of tau (flortaucipir) positron emission tomography (FTP-PET) to autopsy is important to demonstrate the relationship of FTP-PET to neuropathologic findings. METHODS: Autopsies were performed on 26 participants who had antemortem FTP-PET. FTP-PET standardized uptake value ratios (SUVRs) were compared to autopsy diagnoses and Braak tangle stage. Quantitative tau burden was compared to regional FTP-PET signal. RESULTS: Participants with Braak stages of IV or greater had elevated FTP-PET signal. FTP-PET was elevated in participants with Alzheimer's disease. An FTP-PET SUVR cut point of 1.29 was determined to be optimal. Quantitative measurements of hippocampal and temporal lobe tau burden were highly correlated to FTP-PET signal (rho's from 0.61 to 0.70, P ≤ .02). DISCUSSION: Elevated FTP-PET reflects Braak IV or greater neuropathology. Participants with primary age-related tauopathy and hippocampal sclerosis did not show elevated FTP-PET signal. Secondary neuropathologic diagnoses of Alzheimer's disease neuropathologic change can lead to borderline elevated FTP-PET signal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies combining antemortem imaging with neuropathological validation have shown that 18F-flortaucipir PET is highly sensitive for presence of high levels of AD neuropathological change with visual rating positivity corresponding to Braak levels IV or greater [184, 185].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [185]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In support of this finding and the quantitative data presented herein, a recent study of 26 cases comparing flortaucipir PET image and autopsy findings demonstrated a sensitivity of 87% and specificity of 82% for identifying AD-spectrum pathological diagnoses, using quantitative analysis of a mesial, inferior, or middle temporal lobe region of interest.25”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [25]
In the citing paper
“Studies comparing antemortem tau PET imaging with autopsy have begun assessing the ability of flortaucipir to detect underlying NFTs in AD and non-AD dementias.25,26,27,28,29,30,31,32,33”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [25]
In the citing paper
“Twelve of these autopsy-confirmed cases had pathological evidence of Braak stages IV to VI NFTs (2 cases with Braak stage IV) with moderate to frequent neuritic plaques and were above the SUVR threshold for positivity for the [18F]flortaucipir temporal lobe region of interest.”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Self-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894 · cited 1×
“Mean (SD) 18 (8) 29 24 27 (2) 22 (6) 28 (1) 26 (4) 21 22 (7) GMWMPVCNPiB SUVR†”
Self-citationNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467
Self-citation
Cited by
Sorted by citations
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationFour distinct trajectories of tau deposition identified in Alzheimer’s disease
Initiative, T. A. D. N., Vogel, J. W., Young, A. L., Oxtoby, N. P., Smith, R., Ossenkoppele, R., Strandberg, O. T., La Joie, R., Aksman, L. M., Grothe, M. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01309-6 · Cited by 741
Performance of plasma phosphorylated tau 181 and 217 in the community
Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01822-2 · Cited by 465
Self-citationFleisher, A. S., Pontecorvo, M. J., Devous, M. D., Lu, M., Arora, A. K., Truocchio, S. P., Aldea, P., Flitter, M., Locascio, T., Devine, M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0528 · Cited by 448
Self-citationMoloney, C. M., Lowe, V. J., & Murray, M. E. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12321 · Cited by 358
Self-citationDeveloping the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H. J., Cummings, J. L., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 351
Self-citationOssenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1858 · Cited by 311
18F-MK-6240 PET for early and late detection of neurofibrillary tangles
Pascoal, T. A., Therriault, J., Benedet, A. L., Savard, M., Lussier, F. Z., Chamoun, M., Tissot, C., Qureshi, M. N. I., Kang, M. S., Mathotaarachchi, S. S., et al. (2020) · Brain · doi:10.1093/brain/awaa180 · Cited by 263
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02443-z · Cited by 249
Mielke, M. M., Frank, R. D., Dage, J. L., Jeromin, A., Ashton, N. J., Blennow, K., Karikari, T. K., Vanmechelen, E., Zetterberg, H., Algeciras-Schimnich, A., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.2293 · Cited by 244
Self-citationImaging biomarkers in neurodegeneration: current and future practices
Young, P. N. E., Estarellas, M., Coomans, E. M., Srikrishna, M., Beaumont, H., Maaß, A., Venkataraman, A. V., Lissaman, R., Jiménez, D., Betts, M. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00612-7 · Cited by 244
Microglial activation and tau burden predict cognitive decline in Alzheimer’s disease
Malpetti, M., Kievit, R. A., Passamonti, L., Jones, P. S., Tsvetanov, K. A., Rittman, T., Mak, E., Nicastro, N., Bevan-Jones, W. R., Su, L., et al. (2020) · Brain · doi:10.1093/brain/awaa088 · Cited by 194
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 221
“Studies combining antemortem imaging with neuropathological validation have shown that 18 F-fl ortaucipir PET is highly sensitive for presence of high levels of AD neuropathological change with visual rating positivity corresponding to Braak levels IV or greater [184, 185].”
Soleimani‐Meigooni, D. N., Iaccarino, L., Joie, R. L., Baker, S. L., Bourakova, V., Boxer, A. L., Edwards, L., Eser, R. A., Gorno‐Tempini, M., Jagust, W. J., et al. (2020) · Brain · doi:10.1093/brain/awaa276 · Cited by 186
Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151
Predicting amyloid PET and tau PET stages with plasma biomarkers
Jack, C. R., Wiste, H. J., Algeciras‐Schimnich, A., Figdore, D. J., Schwarz, C. G., Lowe, V. J., Ramanan, V. K., Vemuri, P., Mielke, M. M., Knopman, D. S., et al. (2023) · Brain · doi:10.1093/brain/awad042 · Cited by 154
Self-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 163
Self-citationTau PET Imaging in Neurodegenerative Disorders
Groot, C., Villeneuve, S., Smith, R., Hansson, O., & Ossenkoppele, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263196 · Cited by 137
Ossenkoppele, R., Reimand, J., Smith, R. A., Leuzy, A., Strandberg, O. T., Palmqvist, S., Stomrud, E., Zetterberg, H., Initiative, T. A. D. N., Scheltens, P., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114398 · Cited by 130
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Koppisetti, R. K., Janelidze, S., Barthélemy, N. R., He, Y., Sato, C., Gordon, B. A., Jiang, H., Benzinger, T. L. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03617-7 · Cited by 164
Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial design
Toledo, J. B., Ruiz, C. A., Weil, R. S., Ferreira, D., Rodriguez‐Porcel, F. E., Pilotto, A., Wyman‐Chick, K. A., Grothe, M. J., Kane, J. P. M., Taylor, A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12814 · Cited by 112
Self-citationOssenkoppele, R., Salvadó, G., Janelidze, S., Binette, A. P., Bali, D., Karlsson, L., Palmqvist, S., Mattsson, N., Stomrud, E., Therriault, J., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00835-z · Cited by 144
Self-citationGallego-Rudolf, J., Wiesman, A. I., Binette, A. P., Villeneuve, S., & Baillet, S. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01763-8 · Cited by 109
Tezuka, T., Takahata, K., Seki, M., Tabuchi, H., Momota, Y., Shiraiwa, M., Suzuki, N., Morimoto, A., Nakahara, T., Iwabuchi, Y., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab190 · Cited by 85
Relevance of biomarkers across different neurodegenerative diseases
Ehrenberg, A. J., Khatun, A., Coomans, E. M., Betts, M. J., Capraro, F., Thijssen, E. H., Senkevich, K. A., Bharucha, T., Jafarpour, M., Young, P. N. E., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00601-w · Cited by 81
Iaccarino, L., Burnham, S. C., Dell’Agnello, G., Dowsett, S. A., & Epelbaum, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.43 · Cited by 87
Current directions in tau research: Highlights from Tau 2020
Sexton, C. E., Snyder, H. M., Beher, D., Boxer, A. L., Brannelly, P., Brion, J., Buée, L., Cacace, A. M., Chételat, G., Citron, M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12452 · Cited by 89
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 87
Self-citationPeet, B. T., Spina, S., Mundada, N., & La Joie, R. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01101-x · Cited by 74
Moloney, C. M., Labuzan, S. A., Crook, J. E., Siddiqui, H., Castanedes‐Casey, M., Lachner, C., Petersen, R. C., Duara, R., Graff‐Radford, N. R., Dickson, D. W., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12749 · Cited by 76
Self-citationA Multilevel View of the Development of Alzheimer’s Disease
Ávila, J., & Perry, G. L. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.015 · Cited by 69
Asken, B. M., & Rabinovici, G. D. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01197-4 · Cited by 70
Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic
Altomare, D., Stampacchia, S., Ribaldi, F., Tomczyk, S., Chevalier, C., Poulain, G., Asadi, S., Bancila, B., Marizzoni, M., Martins, M., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330619 · Cited by 65
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62
International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease
Tian, M., Civelek, A. C., Carrió, I., Watanabe, Y., Kang, K. W., Murakami, K., Garibotto, V., Prior, J. O., Barthel, H., Zhou, R., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05673-w · Cited by 62
Ghirelli, A., Tosakulwong, N., Weigand, S. D., Clark, H. M., Ali, F., Botha, H., Duffy, J. R., Utianski, R. L., Buciuc, M., Murray, M. E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25893 · Cited by 59
Self-citationAgüero, C., Dhaynaut, M., Amaral, A. C. S., Moon, S., Neelamegam, R., Scapellato, M., Carazo-Casas, C., Kumar, S., Fakhri, G. E., Johnson, K. A., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02672-z · Cited by 55
Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults
Chen, X., Cassady, K. E., Adams, J. N., Harrison, T. M., Baker, S. L., & Jagust, W. J. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2111-20.2020 · Cited by 61
Murray, M. E., Moloney, C. M., Kouri, N., Syrjanen, J. A., Matchett, B. J., Rothberg, D. M., Tranovich, J. F., Sirmans, T. N. H., Wiste, H. J., Boon, B. D. C., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00578-0 · Cited by 58
Self-citationOssenkoppele, R., Coomans, E. M., Apostolova, L. G., Baker, S. L., Barthel, H., Beach, T. G., Benzinger, T. L. S., Betthauser, T. J., Bischof, G. N., Bottlaender, M., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02000-6 · Cited by 60
Self-citationBischof, G. N., Dodich, A., Boccardi, M., van Eimeren, T., Festari, C., Barthel, H., Hansson, O., Nordberg, A. K., Ossenkoppele, R., Sabri, O., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05156-4 · Cited by 54
Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease
Trelle, A. N., Carr, V. A., Wilson, E. N., Swarovski, M. S., Hunt, M. P., Toueg, T. N., Tran, T., Channappa, D., Corso, N. K., Thieu, M. K., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011477 · Cited by 52
Groot, C., Smith, R. A., Stomrud, E., Binette, A. P., Leuzy, A., Wuestefeld, A., Wisse, L. E. M., Palmqvist, S., Mattsson, N., Janelidze, S., et al. (2022) · Brain · doi:10.1093/brain/awac329 · Cited by 53
Moscoso, A., Karikari, T. K., Grothe, M. J., Ashton, N. J., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., & Schöll, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12570 · Cited by 50
Abnormal tau in amyloid PET negative individuals
Yoon, B., Guo, T., Provost, K., Korman, D., Ward, T. J., Landau, S. M., & Jagust, W. J. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.09.019 · Cited by 52
Costoya‐Sánchez, A., Moscoso, A., Silva‐Rodríguez, J., Pontecorvo, M. J., Devous, M. D., Aguiar, P., Schöll, M., Grothe, M. J., Initiative, A. D. N., Weiner, M. W., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.2560 · Cited by 52
Self-citationWolters, E. E., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Hansson, O., Nordberg, A. K., Frisoni, G. B., Garibotto, V., & Ossenkoppele, R. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05118-w · Cited by 48
What’s the cut-point?: a systematic investigation of tau PET thresholding methods
Weigand, A. J., Maaß, A., Eglit, G. L., & Bondi, M. W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00986-w · Cited by 49
Neuropathology of the Alzheimer's continuum: an update
Jellinger, K. A. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3050 · Cited by 52
Diagnostic biomarkers in Alzheimer’s disease
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 55
Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET
Cogswell, P. M., Lundt, E. S., Therneau, T. M., Wiste, H. J., Graff‐Radford, J., Algeciras‐Schimnich, A., Lowe, V. J., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13539 · Cited by 38
Self-citationDiagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
Altomare, D., Caprioglio, C., Assal, F., Allali, G., Mendes, A., Ribaldi, F., Ceyzériat, K., Martins, M., Tomczyk, S., Stampacchia, S., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05246-x · Cited by 40
Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model
Therneau, T. M., Knopman, D. S., Lowe, V. J., Botha, H., Graff‐Radford, J., Jones, D. T., Vemuri, P., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118440 · Cited by 36
Self-citationGiorgio, J., Jagust, W. J., Baker, S. L., Landau, S. M., Peter Tiňo, B., Kourtzi, Z., & Initiative, A. D. N. (2022) · Nature Communications · doi:10.1038/s41467-022-28795-7 · Cited by 40
Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome
Corriveau‐Lecavalier, N., Botha, H., Graff‐Radford, J., Switzer, A. R., Przybelski, S. A., Wiste, H. J., Murray, M. E., Reichard, R. R., Dickson, D. W., Nguyen, A. T., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae183 · Cited by 47
Self-citation[ 18 F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
Wolters, E. E., Papma, J. M., Verfaillie, S. C. J., Visser, D., Weltings, E., Groot, C., van der Ende, E. L., Giannini, L. A. A., Tuncel, H., Timmers, T., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012448 · Cited by 37
Albrecht, D. S., Sagare, A., Pachicano, M., Sweeney, M. D., Toga, A., Zlokovic, B., Chui, H., Joe, E., Schneider, L., Morris, J. C., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.01.010 · Cited by 37
“FTP PET signal in these areas has been shown to correspond well with tau burden in post mortem samples (Lowe et al., 2020).”
BackgroundJosephs, K. A., Tosakulwong, N., Weigand, S. D., Graff‐Radford, J., Schwarz, C. G., Senjem, M. L., Machulda, M. M., Kantarci, K., Knopman, D. S., Nguyen, A. T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado8076 · Cited by 40
Self-citationRubinski, A., Franzmeier, N., Dewenter, A., Luan, Y., Smith, R. A., Strandberg, O. T., Ossenkoppele, R., Dichgans, M., Hansson, O., Ewers, M., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01074-9 · Cited by 41
P-tau217 in Alzheimer’s disease
Telser, J., Risch, L., Saely, C. H., Grossmann, K., & Werner, P. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.03.018 · Cited by 32
Evaluation of [ 18 F]-JNJ-64326067-AAA tau PET tracer in humans
Baker, S. L., Provost, K., Thomas, W., Whitman, A., Janabi, M., Schmidt, M. E., Timmers, M., Kolb, H. C., Rabinovici, G. D., & Jagust, W. J. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211031035 · Cited by 33
Phillips, J. S., Nitchie, F. J., Re, F. D., Olm, C. A., Cook, P. A., McMillan, C. T., Irwin, D. J., Gee, J. C., Dubroff, J. G., Grossman, M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12456 · Cited by 33
Freiburghaus, T., Pawlik, D., Hauer, K. O., Ossenkoppele, R., Strandberg, O. T., Leuzy, A., Rittmo, J. Ö., Tremblay, C., Serrano, G. E., Pontecorvo, M. J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02801-2 · Cited by 34
Boon, B. D. C., Piura, Y. D., Moloney, C. M., Chalk, J. L., Lincoln, S., Rutledge, M. H., Rothberg, D. M., Kouri, N., Hinkle, K. M., Roemer, S. F., et al. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00313-8 · Cited by 37
Self-citationImaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography
Mak, E., Nicastro, N., Malpetti, M., Savulich, G., Surendranathan, A., Holland, N., Passamonti, L., Jones, P. S., Carter, S. F., Su, L., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.11.006 · Cited by 30
White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease
Tian, J., Raghavan, S., Reid, R. I., Przybelski, S. A., Lesnick, T. G., Gebre, R. K., Graff-Radford, J., Schwarz, C. G., Lowe, V. J., Kantarci, K., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207250 · Cited by 29
Self-citationSynthesizing images of tau pathology from cross-modal neuroimaging using deep learning
Lee, J., Burkett, B. J., Min, H.-K. P., Senjem, M. L., Dicks, E., Corriveau‐Lecavalier, N., Mester, C. T., Wiste, H. J., Lundt, E. S., Murray, M. E., et al. (2023) · Brain · doi:10.1093/brain/awad346 · Cited by 32
Self-citationBurnham, S. C., Iaccarino, L., Pontecorvo, M. J., Fleisher, A., Lu, M., Collins, E. C., & Devous, M. D. (2023) · Brain Communications · doi:10.1093/braincomms/fcad305 · Cited by 30
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W
Qi, C., Lövestam, S., Murzin, A. G., Peak‐Chew, S., Franco, C. D. M. F., Bogdani, M., Latimer, C. S., Murrell, J. R., Cullinane, P. W., Jaunmuktane, Z., et al. (2025) · Nature Structural & Molecular Biology · doi:10.1038/s41594-025-01498-5 · Cited by 27
Development, initial validation, and application of a visual read method for [ 18 F]MK‐6240 tau PET
Shuping, J., Matthews, D. C., Adamczuk, K., Scott, D., Rowe, C. C., Kreisl, W. C., Johnson, S. C., Lukic, A. S., Johnson, K. A., Rosa‐Neto, P., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12372 · Cited by 26
Chen, X., Toueg, T. N., Harrison, T. M., Baker, S. L., & Jagust, W. J. (2023) · Annals of Neurology · doi:10.1002/ana.26813 · Cited by 27
Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years
Josephs, K. A., Weigand, S. D., & Whitwell, J. L. (2022) · Neurology · doi:10.1212/wnl.0000000000200287 · Cited by 39
Burkett, B. J., Johnson, D. R., & Lowe, V. J. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266463 · Cited by 27
Self-citationKotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A., Mintun, M. A., Devous, M. D., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01160-6 · Cited by 25
Multimodal in vivo and postmortem assessments of tau in Lewy body disorders
Coughlin, D. G., Phillips, J. S., Roll, E. E., Peterson, C. S., Lobrovich, R., Rascovsky, K., Ungrady, M. B., Wolk, D. A., Das, S. R., Weintraub, D. A., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.08.003 · Cited by 23
The many faces of globular glial tauopathy: A clinical and imaging study
Buciuc, M., Koga, S., Pham, N. T. T., Duffy, J. R., Knopman, D. S., Ali, F., Boeve, B. F., Graff‐Radford, J., Botha, H., Lowe, V. J., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15603 · Cited by 24
Self-citationLongitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies
Chen, Q., Przybelski, S. A., Senjem, M. L., Schwarz, C. G., Lesnick, T. G., Botha, H., Knopman, D. S., Graff‐Radford, J., Savica, R., Jones, D. T., et al. (2022) · Movement Disorders · doi:10.1002/mds.28973 · Cited by 23
Self-citationMRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous
Josephs, K. A., Tosakulwong, N., Graff‐Radford, J., Weigand, S. D., Buciuc, M., Machulda, M. M., Jones, D. T., Schwarz, C. G., Senjem, M. L., Ertekin‐Taner, N., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51038 · Cited by 22
Self-citationKara, F., Joers, J. M., Deelchand, D. K., Park, Y. W., Przybelski, S. A., Lesnick, T. G., Senjem, M. L., Zeydan, B., Knopman, D. S., Lowe, V. J., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.12.010 · Cited by 22
Self-citationKandiah, N., Choi, S. H., Hu, C., Ishii, K., Kasuga, K., & Mok, V. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220059 · Cited by 25
Malpetti, M., Kaalund, S. S., Tsvetanov, K. A., Rittman, T., Briggs, M., Allinson, K. S. J., Passamonti, L., Holland, N., Jones, P. S., Fryer, T. D., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262985 · Cited by 21
Tau burden is best captured by magnitude and extent: Tau‐MaX as a measure of global tau
Brown, C., Das, S. R., Cousins, K. A. Q., Tropea, T. F., Plotkin, A., Detre, J. A., Yushkevich, P. A., McMillan, C. T., Lee, E. B., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70346 · Cited by 20
ACR Appropriateness Criteria® Dementia: 2024 Update
Soderlund, K. A., Austin, M. J., Ben‐Haim, S., Chu, S., Ivanidze, J., Joshi, P., Kalnins, A., Kennedy, M., Kulshreshtha, A., Kuo, P. H., et al. (2025) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2025.02.031 · Cited by 22
Preclinical Characterization of the Tau PET Tracer [18F]SNFT-1: Comparison of Tau PET Tracers
Harada, R., Lerdsirisuk, P., Shimizu, Y., Yokoyama, Y., Du, Y., Kudo, K., Ezura, M., Ishikawa, Y., Iwata, R., Shidahara, M., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265593 · Cited by 20
The Role of Tau in Neuronal Function and Neurodegeneration
Aranda-Abreu, G. E., Rojas-Durán, F., Hernández‐Aguilar, M. E., Herrera‐Covarrubias, D., García, L. I., Toledo‐Cárdenas, M. R., & Chi-Castañeda, D. (2025) · Neurology International · doi:10.3390/neurolint17050075 · Cited by 20
Pawlik, D., Leuzy, A., Strandberg, O. T., & Smith, R. A. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117193 · Cited by 23
Liu, W., Initiative, A. D. N., Au, L. W. C., Abrigo, J., Luo, Y., Wong, A., Lam, B. Y. K., Fan, X., Kwan, P. W.-L., Ma, H. W., et al. (2021) · Aging · doi:10.18632/aging.203082 · Cited by 20
Jin, Z., Lu, Y., Tang, H., & Cui, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70472 · Cited by 24
Richardson, T. E., Walker, J. M., Farrell, K. W., Oliveira, T. G., White, C. L., & Crary, J. F. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02943-x · Cited by 25
Towards cascading genetic risk in Alzheimer’s disease
Altmann, A., Aksman, L. M., Oxtoby, N. P., Young, A. L., ADNI, Weiner, M., Aisen, P., Petersen, R., Weiner, M., Aisen, P., et al. (2024) · Brain · doi:10.1093/brain/awae176 · Cited by 18
Self-citationRecent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease
Buckley, R. F. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01026-5 · Cited by 18
Bisi, N., Pinzi, L., Rastelli, G., & Tonali, N. (2024) · Molecules · doi:10.3390/molecules29030722 · Cited by 17
Moscoso, A., Grothe, M. J., Schöll, M., & Initiative, A. D. N. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05195-5 · Cited by 16
Gatto, R. G., Carlos, A. F., Reichard, R. R., Lowe, V. J., Whitwell, J. L., & Josephs, K. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284182 · Cited by 17
Self-citationMastrangelo, A., Caldera, S., Mastenbroek, S. E., Vittoriosi, E., Janelidze, S., Serrano, G. E., Atri, A., Shill, H. A., Driver‐Dunckley, E. D., Mehta, S. H., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02904-4 · Cited by 15
Serrano‐Pozo, A., Escott‐Price, V., Grinberg, L. T., Pascoal, T. A., Suárez‐Calvet, M., Dubois, B., & Sperling, R. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00198-4 · Cited by 20
Qiao, Z., Wang, G., Zhao, X. B., Wang, K., Fan, D., Chen, Q., & Ai, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.841942 · Cited by 15
Moscoso, A., Wren, M. C., Lashley, T., Årstad, E., Murray, M. E., Fox, N. C., Sander, K., & Schöll, M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00543-x · Cited by 18
Self-citationMedial temporal tau predicts memory decline in cognitively unimpaired elderly
Kwan, A. T. H., Arfaie, S., Therriault, J., Azizi, Z., Lussier, F. Z., Tissot, C., Chamoun, M., Bezgin, G., Servaes, S., Stevenon, J., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac325 · Cited by 15
Metadata
- Authors
- Lowe, V. J., Lundt, E. S., Albertson, S. M., Min, H., Fang, P., Przybelski, S. A., Senjem, M. L., Schwarz, C. G., Kantarci, K., Boeve, B., Jones, D. T., Reichard, R. R., Tranovich, J. F., Hanna Al‐Shaikh, F. S., Knopman, D. S., Jack, C. R., Dickson, D. W., Petersen, R. C., & Murray, M. E.
- Affiliations
- Mayo Clinic (US)
- Department of Neuroscience Mayo Clinic Jacksonville FL USA
- Corresponding author
- Lowe, Val J.
- Murray, Melissa E.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2020-01-04
- Volume
- 16
- Issue
- 3
- Pages
- 561-571
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC7067654
- OpenAlex
- W2991594523
- Cited by
- 203
- References
- 44
- Citations by year
- 2026: 26 · 2025: 37 · 2024: 28 · 2023: 30 · 2022: 33 · 2021: 30 · 2020: 18
- FWCI
- 15.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (P50 AG016574, R01 NS89757, R01 NS089544, R01 DC10367, R01 AG011378, R01 AG041851, R01 AG034676, R01 AG054449, R01 NS097495, U01 AG006786, R21 NS094489)
- Robert Wood Johnson Foundation
- Mayo Foundation for Medical Education and Research
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- tau PET, flortaucipir
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Autopsy, Brain, Female, Humans, Male, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
